$PHAT
Phathom Pharmaceuticals, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021042895 Filed on August 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.72M $5.160M
YoY Change 165.93% 282.22%
% of Gross Profit
Research & Development $21.60M $14.86M
YoY Change 45.35% 436.04%
% of Gross Profit
Depreciation & Amortization $131.0K $77.00K
YoY Change 70.13%
% of Gross Profit
Operating Expenses $35.32M $20.02M
YoY Change 76.41% -75.88%
Operating Profit -$35.32M -$20.02M
YoY Change 76.41% -75.88%
Interest Expense $1.256M $1.262M
YoY Change -0.48% -221.35%
% of Operating Profit
Other Income/Expense, Net -$1.233M -$1.080M
YoY Change 14.17% -77.25%
Pretax Income -$36.55M -$21.10M
YoY Change 73.23% -75.96%
Income Tax
% Of Pretax Income
Net Earnings -$36.55M -$21.10M
YoY Change 73.22% -75.96%
Net Earnings / Revenue
Basic Earnings Per Share -$1.00
Diluted Earnings Per Share -$1.00 -$823.9K
COMMON SHARES
Basic Shares Outstanding 36.64M
Diluted Shares Outstanding 36.64M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $209.7M $247.3M
YoY Change -15.22% 198.31%
Cash & Equivalents $209.7M $247.3M
Short-Term Investments
Other Short-Term Assets $1.669M $1.400M
YoY Change 19.21% -12.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $211.3M $248.7M
YoY Change -15.02% 194.32%
LONG-TERM ASSETS
Property, Plant & Equipment $803.0K $3.400M
YoY Change -76.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $291.0K $400.0K
YoY Change -27.25% 33.33%
Total Long-Term Assets $3.241M $3.700M
YoY Change -12.41% 825.0%
TOTAL ASSETS
Total Short-Term Assets $211.3M $248.7M
Total Long-Term Assets $3.241M $3.700M
Total Assets $214.6M $252.4M
YoY Change -14.98% 197.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.401M $4.900M
YoY Change 10.22% 880.0%
Accrued Expenses $8.845M $7.000M
YoY Change 26.36% 250.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $10.35M $1.400M
YoY Change 638.93%
Total Short-Term Liabilities $39.61M $13.30M
YoY Change 197.83% -90.81%
LONG-TERM LIABILITIES
Long-Term Debt $37.34M $44.90M
YoY Change -16.84% 100.45%
Other Long-Term Liabilities $4.125M $5.900M
YoY Change -30.08% 180.95%
Total Long-Term Liabilities $41.47M $50.80M
YoY Change -18.38% 107.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.61M $13.30M
Total Long-Term Liabilities $41.47M $50.80M
Total Liabilities $82.45M $64.00M
YoY Change 28.83% -62.2%
SHAREHOLDERS EQUITY
Retained Earnings -$456.9M
YoY Change
Common Stock $589.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $132.1M $188.4M
YoY Change
Total Liabilities & Shareholders Equity $214.6M $252.4M
YoY Change -14.98% 197.29%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$36.55M -$21.10M
YoY Change 73.22% -75.96%
Depreciation, Depletion And Amortization $131.0K $77.00K
YoY Change 70.13%
Cash From Operating Activities -$28.36M -$9.340M
YoY Change 203.63% 79.27%
INVESTING ACTIVITIES
Capital Expenditures -$44.00K -$50.00K
YoY Change -12.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$44.00K -$50.00K
YoY Change -12.0% -99.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 106.0K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -28.36M -9.340M
Cash From Investing Activities -44.00K -50.00K
Cash From Financing Activities 106.0K 0.000
Net Change In Cash -28.30M -9.390M
YoY Change 201.35% -111.34%
FREE CASH FLOW
Cash From Operating Activities -$28.36M -$9.340M
Capital Expenditures -$44.00K -$50.00K
Free Cash Flow -$28.32M -$9.290M
YoY Change 204.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
312000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
480000
CY2021Q2 us-gaap Interest Payable Current
InterestPayableCurrent
302000
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
10345000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
39611000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8845000
CY2021Q2 phat Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
14238000
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
37340000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10606000
CY2020Q4 phat Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
19997000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-456882000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
132128000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
214579000
CY2021Q2 phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
905000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
182000
us-gaap Investment Income Interest
InvestmentIncomeInterest
27000
CY2021Q2 us-gaap Interest Expense
InterestExpense
1256000
CY2020Q2 us-gaap Interest Expense
InterestExpense
1262000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
35319000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
20021000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
589007000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42178000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31329613
us-gaap Operating Expenses
OperatingExpenses
68903000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29186169
CY2020Q2 phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
249000
phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
1846000
phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
653000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21597000
CY2021Q2 phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
0
CY2020Q2 phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
34000
phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
16000
phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
77000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13722000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5162000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26725000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-35319000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20021000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68903000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q2 us-gaap Liabilities
Liabilities
82451000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7353000
CY2020Q4 us-gaap Liabilities
Liabilities
100840000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
474000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
55524000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
39634000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1375000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31262769
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1557000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4125000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4125000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28516010
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
579755000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-385487000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
194271000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
295111000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14859000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1233000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1080000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2492000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-846000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-36552000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-21101000
us-gaap Net Income Loss
NetIncomeLoss
-71395000
us-gaap Net Income Loss
NetIncomeLoss
-41242000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.26
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32997099
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36468498
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32733750
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
194271000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
412000
CY2021Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
323000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3818000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
358000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-34843000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
164339000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4237000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-36552000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
132128000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y21D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M26D
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30724000
us-gaap Operating Expenses
OperatingExpenses
40396000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40396000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1060000
us-gaap Interest Expense
InterestExpense
2528000
us-gaap Interest Expense
InterestExpense
2000000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-95000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36636164
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
227955000
CY2020Q1 phat Adjustments To Additional Paid In Capital Conversion Of Warrant Liability Into Equity
AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity
318000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
563000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-20141000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
208695000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
828000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-21101000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
188423000
us-gaap Profit Loss
ProfitLoss
-71395000
us-gaap Profit Loss
ProfitLoss
-41242000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
256000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
129000
us-gaap Share Based Compensation
ShareBasedCompensation
8055000
us-gaap Share Based Compensation
ShareBasedCompensation
1391000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
698000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
544000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-95000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-540000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
phat Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
82000
phat Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9672000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
587000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
209669000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
247271000
us-gaap Interest Paid Net
InterestPaidNet
1833000
us-gaap Interest Paid Net
InterestPaidNet
1309000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
20000
phat Non Cash Final Interest Payment Fee
NonCashFinalInterestPaymentFee
2063000
phat Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock
NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock
358000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2203000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10428000
phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
722000
phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
-181000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-12860000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8129000
phat Increase Decrease In Clinical Accrued Trial Expenses
IncreaseDecreaseInClinicalAccruedTrialExpenses
-5759000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-10000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
146000
phat Increase Decrease In Operating Right Of Use Asset And Lease Liabilities
IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
50000
phat Increase Decrease In Operating Right Of Use Asset And Lease Liabilities
IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
9000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-93000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78129000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20761000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
214000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
733000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-214000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-733000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
516000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
516000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-77827000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3506000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
287496000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
243765000
phat Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock
NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock
323000
phat Operating Lease Liabilities Arising From Obtaining Right Of Use Assets
OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
1423000
phat Conversion Of Warrant Liabilities Into Equity
ConversionOfWarrantLiabilitiesIntoEquity
318000
us-gaap Depreciation
Depreciation
129000
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1317000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
331000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
803000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</p>
CY2021Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p>
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
986000
CY2021Q2 us-gaap Depreciation
Depreciation
131000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1390000
CY2020Q2 us-gaap Depreciation
Depreciation
77000
us-gaap Depreciation
Depreciation
256000
CY2021Q2 phat Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3501000
CY2020Q4 phat Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
4864000
CY2021Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3884000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4587000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1436000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1123000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
24000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
32000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8845000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10606000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
phat Purchase Commitment Expense
PurchaseCommitmentExpense
0
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2147000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2373000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2147000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2373000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
480000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
474000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1375000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1557000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1855000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2031000
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
700000
CY2021Q2 phat Long Term Debt Maturities Repayments Of Principal And Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear
1843000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
246000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
503000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
516000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
529000
CY2021Q2 phat Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
342000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2136000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
281000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1855000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
480000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1375000
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0725
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
10345000
CY2021Q2 phat Long Term Debt Noncurrent Excluding Unamortized Debt Discount
LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount
39655000
CY2021Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2315000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
47685000
CY2021Q2 phat Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths
23667000
CY2021Q2 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo
22146000
CY2021Q2 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree
12904000
CY2021Q2 phat Long Term Debt And Interest
LongTermDebtAndInterest
60560000
CY2021Q2 phat Debt Instrument Interest And Final Payment Fee
DebtInstrumentInterestAndFinalPaymentFee
10560000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2746759
phat Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting
603315
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2143444
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14879587
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.75
CY2021Q1 phat Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled
DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
8356
CY2021Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.75
CY2021Q2 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.75
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2728742
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.36
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
34432000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1511500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
38.77
phat Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercised And Shares Vested
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested
44998
phat Share Based Compensation Arrangements By Share Based Payment Award Options Exercises And Shares Vested In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice
11.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
95105
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
33.88
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4100139
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.60
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
34607000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
655538
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.36
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
12352000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
53000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6738
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6372
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0064
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0082
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4237000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
828000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8055000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1391000

Files In Submission

Name View Source Status
0001564590-21-042895-index-headers.html Edgar Link pending
0001564590-21-042895-index.html Edgar Link pending
0001564590-21-042895.txt Edgar Link pending
0001564590-21-042895-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
phat-10q_20210630.htm Edgar Link pending
phat-10q_20210630_htm.xml Edgar Link completed
phat-20210630.xsd Edgar Link pending
phat-20210630_cal.xml Edgar Link unprocessable
phat-20210630_def.xml Edgar Link unprocessable
phat-20210630_lab.xml Edgar Link unprocessable
phat-20210630_pre.xml Edgar Link unprocessable
phat-ex101_150.htm Edgar Link pending
phat-ex102_106.htm Edgar Link pending
phat-ex103_174.htm Edgar Link pending
phat-ex104_267.htm Edgar Link pending
phat-ex105_416.htm Edgar Link pending
phat-ex311_9.htm Edgar Link pending
phat-ex312_8.htm Edgar Link pending
phat-ex321_7.htm Edgar Link pending
phat-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending